An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Clinical trial NCT05809531 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05809531
Sponsor: Apellis Pharmaceuticals, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

C3G IC-MPGN C3 Glomerulopathy C3 Glomerulonephritis Complement 3 Glomerulopathy Complement 3 Glomerulopathy (C3G)Complement 3 Glomerulonephritis Dense Deposit Disease DDD Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Start date: 2023-05-29
Primary completion: 2027-07-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.